News and Events
News and Events
You may sort news and events by title or recency. If you wish to view only news, please select the news link from the left. If you wish to see events at which Quintiles is scheduled to participate, please select the events link from the left.
- Sort by: Most Recent
- Title
-
QUINTILES COMPLETES ACQUISITION OF BRI INTERNATIONAL
Nov. 22, 1996 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced today that it has completed the acquisition of BRI International, Inc., an international contract research organization with approximately 500 employees. -
QUINTILES ANNOUNCES EXECUTIVE APPOINTMENTS
October 30, 1996 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced today two appointments to executive positions. -
QUINTILES, MINIDOC SIGN GLOBAL MARKETING AGREEMENT FOR TECHNOLOGY & SERVICES TO SPEED CLINICAL RESEARCH
Oct. 2, 1996 - MiniDoc AB and Quintiles, Inc., The U.S. division of one of the largest contract research organizations (CRO) in the world, have signed a global sales and marketing agreement. The agreement covers all of MiniDoc's services and products in the field of data collection in clinical research. -
QUINTILES SIGNS DEFINITIVE AGREEMENT TO ACQUIRE BRI INTERNATIONAL
September 18, 1996 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced today the signing of a definitive agreement to acquire BRI International, Inc., a global contract research organization based in Arlington, Va. Quintiles announced in July that it had entered into a non-binding letter of intent to acquire BRI. -
QUINTILES BREAKS GROUND IN BATHGATE, SCOTLAND, FOR PACKAGING & DISTRIBUTION, DATA MANAGEMENT FACILITY
AUGUST 12, 1996 - Quintiles Transnational Corp. (Nasdaq: QTRN) today broke ground for a 171,000-square-foot clinical trials material packaging and distribution center in Bathgate, Scotland, 20 miles west of Edinburgh. The facility, which also will house a clinical data management service, is expected to be operational in fall 1997 and eventually will employ about 300 people. -
QUINTILES CONSIDERS ACQUISITION OF BRI INTERNATIONAL
July 31, 1996 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced today the signing of a non-binding letter of intent to acquire BRI International, Inc., a global contract research organization based in Arlington, Va. If completed, the acquisition of BRI International is expected to enhance Quintiles' resources and expertise in the areas of medical devices, good manufacturing practices (GMP), and worldwide clinical and data management services. -
QUINTILES ESTABLISHES OFFICES IN SOUTH AFRICA, VIENNA AND HELSINKI
May 17, 1996 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced that it has established a subsidiary in South Africa and opened new offices in Vienna and Helsinki to help meet the need for drug development services in those areas. Quintiles, a leading contract research organization (CRO), provides drug development services on a global basis for the pharmaceutical and biotechnology industries. -
QUINTILES ANNOUNCES APPOINTMENTS IN QUALITY ASSURANCE, INFORMATION MANAGEMENT AND BUSINESS DEVELOPMENT
May 15, 1996 - Quintiles Transnational Corp. (Nasdaq: QTRN) announces the following appointments: -
QUINTILES COMPLETES ACQUISITION OF SWEDISH CONTRACT RESEARCH ORGANIZATION
February 16, 1996 - Quintiles Transnational Corp.(Nasdaq:QTRN) announced today that it has completed the previously announced acquisition of PMC Contract Research AB located in Uppsala, Sweden. The acquisition expands Quintiles' ability to provide drug development services in Scandinavia and positions the company for further growth in that region. Quintiles is a worldwide drug development firm that provides a full range of contract research services to the pharmaceutical and biotechnology industries. -
QUINTILES SIGNS LETTER OF INTENT TO ACQUIRE SWEDISH CONTRACT RESEARCH ORGANIZATION
February 6, 1996 - Quintiles Transnational Corp. (Nasdaq:QTRN) announced today that it has signed a non-binding letter of intent to acquire 100% of the stock of PMC Contract Research AB located in Uppsala, Sweden. The proposed acquisition would expand Quintiles' ability to provide drug development services in Scandinavia and position the company for further growth in that region. The proposed transaction is subject to the negotiation and execution of a definitive agreement and other approvals.
Page 1 of 1 (10 items)